Lars Y. Terenius
Stockholm, AB 17176, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Effects of Ethanol and Opioid Receptor Antagonists Naltrexone and LY2444296 on the Organization of Cholesterol- and Sphingomyelin-Enriched Plasma Membrane Domains.
Journal: ACS chemical neuroscience
Published: September 26, 2025
Cholesterol modulates trafficking of galanin receptor subtype 1 but not subtype 2: Insights from live-cell imaging.
Journal: British journal of pharmacology
Published: February 25, 2025
Small Molecule Decoy of Amyloid-β Aggregation Blocks Activation of Microglia-Like Cells.
Journal: Journal of Alzheimer's disease : JAD
Published: September 06, 2024
LY2444296, a κ-opioid receptor antagonist, selectively reduces alcohol drinking in male and female Wistar rats with a history of alcohol dependence.
Journal: Scientific reports
Published: January 11, 2024
Small molecular decoys in Alzheimer's disease.
Journal: Neural regeneration research
Published: August 07, 2023
Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane.
Journal: Research square
Published: July 28, 2023
Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane.
Journal: Translational psychiatry
Published: June 21, 2023
Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179.
Journal: Research square
Published: June 19, 2023
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179.
Journal: Nature communications
Published: May 17, 2023
The interwoven fibril-like structure of amyloid-beta plaques in mouse brain tissue visualized using super-resolution STED microscopy.
Journal: Cell & bioscience
Published: May 01, 2023
Small Molecule Decoys of Aggregation for Elimination of Aβ-Peptide Toxicity.
Journal: ACS chemical neuroscience
Published: April 14, 2023
Last Updated: 09/26/2026